Concomitant use of a proton pump inhibitor with the CDK4/6 inhibitor palbociclib in women with advanced breast was associated with worse PFS and overall survival, a retrospective analysis shows.
Prospective data from almost 20,000 people with type 2 diabetes show that proton pump inhibitor use is linked with significantly more cardiovascular disease events and all-cause death than nonuse.